Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status Imatinib mesylate is a selective BCR-ABL tyrosine kinase inhibitor effective in Philadelphia (Ph)-positive chronic myeloid leukaemia (Ph þ CML). In all, 50-90% of newly diagnosed or interferon-a (IFN-a) failing chronic phase (CP) patients treated with this drug at 400-800 mg/day obtain complete cytogenetic response (CCR), which is strongly associated with a very high probability of long-term disease-free survival (DFS). [1] [2] [3] [4] However, gene amplification or point mutations in the Abelson portion of the BCR-ABL fusion gene can cause drug resistance, [5] [6] which is usually accompanied by response failure and/or disease progression. Thus, prognostic indicators to identify patients at high risk of evolution are being developed from accumulation of clinical data with the aim of optimizing CML treatment guidelines.
We report on a Phþ CML patient treated with standard dose of imatinib who, while apparently in CCR at conventional cytogenetic analysis (CCA), went into a biclonal blast crisis. At that time, fluorescence in situ hybridization (FISH) showed Phþ blasts having an interstitial deletion at long arm of chromosome 9. Molecular analyses confirmed coexpression of e1a2 (p190) and e13a2 (p210) fusion transcripts. Sequencing of BCR-ABL fusion transcript revealed a point mutation at the region encoding the catalytic domain of the ABL kinase.
Intensive chemotherapy (CT) induced complete remission and undetectable BCR-ABL transcripts.
Therefore, we critically discuss these clinical-biological variables that are currently under investigation for their prognostic significance and their potential impact on individual patient's disease management.
A 42-year-old man was diagnosed in April 2002 as having CML because of mild leukocytosis (WBC 38 Â 10 9 /l). Hemoglobin was 12.8 g/dl, platelet count was 630 Â 10 9 /l, peripheral blood (PB) and bone marrow (BM) blasts were 0 and 1%, respectively. Hepato-splenomegaly was not present. The Sokal and Euro scores were low. Conventional cytogenetics showed the standard t(9;22)(q34;q11) on 25/25 metaphases. FISH analysis was not performed at that time. No siblings were available for HLA typing. Therapy with IFN-a was started, but was withdrawn after 7 months because of severe toxicity and lack of cytogenetic response (Ph þ cells 100%).
In metaphases, cytological examination showed 40% blasts with two distinct immunophenotypes (one positive for CD34, CD117, HLA-DR, CD13, CD33 and one positive for CD34, CD19, CD22, TdT), indicating a biclonal blast crisis. Despite the absence of Ph þ mitoses at CCA, blasts had a BCR-ABL genomic rearrangement at dual color BCR-ABL FISH analysis (Vysis, Richmond, UK) in 29 out of 54 analysed nuclei, and the deletion of the 5 0 ABL region on the derivative chromosome 9. Two nuclei showed a double Ph, and 23 nuclei were Ph negative. Nested RT-PCR analysis, carried out on 8 Â 10 6 mononuclear BM cells according to the Biomed-1 Concerted Action, 7 resulted positive for the BCR-ABL e1a2 (p190) and e13a2 (p210) fusion transcripts; quantitative RQ-PCR, performed following the standardized method, 8 showed a number of BCR-ABL e1a2 (p190) and e13a2 (p210) copies, normalized to 10 000 copies of ABL gene, of 15.6 and 265.71, respectively. The evaluation for BCR-ABL kinase domain mutations, using a nested RT-PCR with DHPLC-based assay and direct gene sequencing, 9 displayed a mutation in the ABL catalytic domain at the codon 351, with a substitution of AUG codifying for methionine, by ACG codifying for threonine. No material was available from diagnosis to perform molecular studies. As expected, FISH analysis of the BM specimen collected at diagnosis revealed the Ph rearrangement with the deletion of 5 0 ABL sequences at der(9) in 78/115 nuclei. Imatinib was stopped and induction chemotherapy with the FLAG-Ida schedule (fludarabine 25 mg/m 2 , days 2-6, cytosinearabinoside 2g/m 2 , days 2-6, granulocyte-colony-stimulating factor (G-CSF) from day 0, idarubicin 6 mg/m 2 , days 4-6) and Gentuzumab Ozogamicin (GO), 6 mg/m 2 , day 1, was administered, which led to complete hematological and cytogenetic remission (CCA and FISH analysis). After a second course of FLAG-Ida (without GO), CCR was confirmed in two subsequent investigations (April and May 2004) at FISH analysis on 500 nuclei, and molecular studies by RQ-PCR and nested RT-PCR showed undetectable BCR-ABL fusion transcripts.
In June 2004, the patient was submitted to an unrelated allogeneic BM transplantation, and is now at day þ 70 in complete remission and full donor chimerism, as documented at CCA, FISH and nested RT-PCR analyses.
A number of considerations can be drawn from the present case, which, despite early and apparently more than satisfactory response to Imatinib, developed a sudden BC.
Imatinib treatment in CML has significantly lowered the rate of acute transformation, in particular in CP patients obtaining a major cytogenetic response (less than 35% Ph þ cells, MCR) within the first 6 months of treatment, for whom a 0-3% risk of progression in the subsequent 24 months is reported. 10 Based on these results, the development of disease evolution in our CP patient who had obtained an early CCR could not be predictable, albeit another similar case has been reported recently. 11 Furthermore, the CCA performed at the time of BC failed to detect Ph þ metaphases on bone marrow, and only molecular investigations by FISH and RT-PCR were able to reveal the presence of the BCR-ABL e1a2 (p190) and e13a2 (p210) fusion transcripts, together with the deletion of the derivative chromosome 9. Thus, in spite of the strong correlation usually observed, at least during CP, between cytogenetics and molecular PCR analyses, 2 based on our observation we sustain that CCA may not be completely reliable to reflect response and/ or disease status and should always be integrated by molecular FISH and PCR analyses; these latter might help to early identify or predict resistance and/or disease evolution. 2 Our case also carried deletion of the derivative chromosome 9, which can be found in 10-15% of CML patients. 12, 13 The very poor prognostic significance attributed to this anomaly during pre-Imatinib era 12 is now a controversial issue, as discordant results have been reported. 13 In addition, in our patient, the BC was also accompanied by the evidence of mutation of the ABL catalytic domain. Mutations of BCR-ABL gene are frequently found in patients with front line or secondary resistance to Imatinib treatment and those falling within the region encoding the kinase domain are mostly associated with disease progression and, hence, a particularly poor prognosis. 5, 10 They mostly occur in patients with longer disease duration prior to Imatinib and/or showing resistance to this drug, while they are only found in less than 10% of cases with MCR. 5, 6 Nevertheless, the possibility that at least in some cases mutations in the ABL gene can pre-exist the onset of Imatinib has recently been suggested.
14 In our patient, as disease evolved a few months after the start of Imatinib and of CCR achievement, the possibility that the ABL mutation was pre-existent to therapy and only represented a clonal selection cannot be excluded.
In our patient, two additional genetic features associated with adverse prognosis coexisted and at least the deletion at der (9) was present at the onset of disease. At the moment, there are still no published data regarding the tendency of CML patients with der(9) deletions to acquire mutations at BCR-ABL gene, and it will be of great interest to test this issue in a prospective study. Thus, we further support the suggestion by Branford et al 5 that molecular monitoring for ABL mutations in the first months of Imatinib therapy may play a crucial role in detecting patients at high risk of resistance.
Finally, in our patient with a biclonal blast crisis, an intensive CT combining fludarabine, idarubicin and anti-CD33 monoclonal antibody GO resulted in a prompt CR with a molecularly undetectable BCR-ABL transcript. One recent report 15 referred on the feasibility and low toxicity of combining GO with CT as a first-line therapy for acute myeloid leukemia. This combination should thus be more extensively investigated as a remission (possibly pretransplant) induction for BC patients at very poor prognosis.
In conclusion, all features detected in our case indicate as mandatory that every CML patient should be systemically investigated for all potentially adverse factors, by combining CCA, FISH and molecular studies including the screening for point mutations, irrespective of response. Results of large trials capable of establishing the effects by the different characteristics on disease outcome under Imatinib will indicate the weight each of them should have in therapy decision for individual CML patients.
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